MR US Fusion Guided Prostate Biopsy Pre-Requisite (2019)
In recent years, the technique of multiparametric MR imaging (mpMRI) of the prostate has offered the potential to alter the current paradigms for prostate cancer diagnosis, staging, and therapy. Though initially met with skepticism, mpMRI of the prostate is being rapidly adopted as a diagnostic technique in both the academic and community setting throughout the United States. At present, the rationale for use of mpMRI in prostate cancer validation is well recognized, but many concepts await validation, both through further trials and clinical experience within the urologic community. Given the rapid adoption of prostate MRI in clinical practice, it is imperative for contemporary urologists to have a basic knowledge of prostate MRI, the rationale and clinical indication for MRI-targeted biopsy, and techniques for performing MRI-targeted biopsy in clinical practice.
- Practicing urologists
- Urology residents in training
- Radiation oncologists
- Medical oncologists caring for prostate cancer patients
At the conclusion of this activity, participants will be able to:
- Demonstrate the basic principles of multiparametric MR imaging of the prostate.
- Define the conceptual basis and methods for MRI to ultrasound computerized co-registration.
- Establish a practice-specific strategy for clinical implementation of MRI-targeted biopsy in patient management.
- Consider metrics for quality assurance in the conduct of MRI-fusion guided prostate biopsy.
Faculty and Education Council Disclosures
Samir Taneja, MD
The James M. and Janet Riha Neissa Professor of Urologic Oncology
Professor of Urology and Radiology
Director, Division of Urologic Oncology
Co‐Director, Smilow Comprehensive Prostate Cancer Center
GU Program Leader, NYU Perlmutter Cancer Institute
Department of Urology, NYU Langone Medical Center
New York, NY
Peter A. Pinto, MD
Head, Prostate Section
Urologic Oncology Branch
National Cancer Institute
National Institutes of Health
Soroush Rais‐Bahrami, MD
Assistant Professor of Urology and Radiology
University of Alabama at Birmingham
Preston C. Sprenkle, MD
Department of Urology
New Haven, CT
Srinivas Vourganti, MD
Rush University Medical Center
James S. Wysock, MD, MS
Division of Urologic Oncology
Chief, Bellevue Urology Service
NYU Langone Medical Center
New York, NY
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy or higher and submit the program evaluation.
Estimated time to complete this activity: 3.00 hours
Release Date: January, 2019
Expiration Date: January, 2022
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring activity for a maximum of 3.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 3.00 AMA PRA Category 1 Credit™
- 3.00 Non-Physician Participation